BABA vs BH

The Advanced Deterministic Scorecard reveals a mixed financial profile for Alibaba (BABA), with a weak Piotroski F-Score of 4/9 indicating suboptimal financial health, and no available Altman Z-Score limiting distress risk assessment. While valuation metrics appear favorable relative to peers—especially a Price/Sales of 0.41 and Forward P/E of 19.50—earnings growth is sharply negative (YoY EPS down 71%), and recent quarterly beats have reversed into consistent misses over the last four quarters. Strong insider sentiment and a bullish analyst consensus (strong_buy) contrast with deteriorating profitability and weak technical trends (10/100). The stock trades significantly above the Graham Number ($102.68) and intrinsic value estimate ($51.38), suggesting overvaluation unless growth rebounds materially.

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and the absence of an Altman Z-Score prevents a full distress risk assessment. Despite strong recent price performance (+110.4% over 1Y), the stock trades at an extremely high P/E of 217.27 versus negative Forward P/E, signaling earnings deterioration. Profitability metrics are concerning, with a mere 0.54% net margin and 0.35% ROE, well below sector averages. While the balance sheet shows a healthy current ratio and low Price/Book of 0.50, these are overshadowed by unsustainable valuation and weak earnings momentum.